CHRS - CIK 0001512762
The table below shows Coherus BioSciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $115.24M | $103.35M | $216.89M | $82.41M | $97.69M | $159.24M |
| Short-term investments | $51.81M | $88.31M | $20.74M | - | $14.86M | $14.86M |
| Receivables | - | - | - | - | - | - |
| Inventory | $4.83M | $2.05M | $4.51M | $3.52M | $47.64M | $62.16M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $206.03M |
| $460.95M |
| $380.20M |
| $310.18M |
| $369.02M |
| $557.93M |
| Property, plant & equipment | - | $1.63M | $1.91M | $2.26M | $2.91M | $3.33M |
| Goodwill | - | - | - | - | $943.00K | $943.00K |
| Total assets | $266.02M | $516.52M | $439.46M | $371.07M | $505.00M | $674.86M |
| Accounts payable | $11.48M | $24.89M | $37.62M | $40.93M | $21.89M | $76.82M |
| Total current liabilities | $132.33M | $372.30M | $263.63M | $255.04M | $295.57M | $463.00M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $187.40M | $428.75M | $319.64M | $554.54M | $592.97M | $758.96M |
| Retained earnings | -$1.42B | -$1.35B | -$1.31B | -$1.61B | -$1.50B | -$1.49B |
| Total equity | $78.62M | $87.77M | $119.83M | -$183.47M | -$87.97M | -$84.11M |